CRIS Current Research Information System

PANTANI, LUCIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 5.229
NA - Nord America 4.780
EU - Europa 3.026
AF - Africa 346
SA - Sud America 283
Continente sconosciuto - Info sul continente non disponibili 243
OC - Oceania 16
Totale 13.923
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.659
VN - Vietnam 1.690
CN - Cina 1.278
SG - Singapore 1.222
IT - Italia 858
GB - Regno Unito 497
DE - Germania 346
SE - Svezia 327
HK - Hong Kong 290
BR - Brasile 200
FR - Francia 190
IN - India 189
NL - Olanda 172
KR - Corea 159
RU - Federazione Russa 133
CI - Costa d'Avorio 130
IE - Irlanda 107
BD - Bangladesh 96
FI - Finlandia 94
JP - Giappone 67
ZA - Sudafrica 66
TG - Togo 59
SC - Seychelles 58
UA - Ucraina 57
CA - Canada 55
PH - Filippine 44
AR - Argentina 37
AT - Austria 36
EE - Estonia 33
BG - Bulgaria 31
CH - Svizzera 28
TH - Thailandia 28
MX - Messico 27
BE - Belgio 26
PL - Polonia 25
ES - Italia 22
JO - Giordania 22
ID - Indonesia 18
TW - Taiwan 18
IQ - Iraq 17
TR - Turchia 15
AU - Australia 14
EC - Ecuador 14
NG - Nigeria 14
IR - Iran 12
SA - Arabia Saudita 12
CZ - Repubblica Ceca 11
CL - Cile 10
CO - Colombia 8
JM - Giamaica 8
MY - Malesia 8
GT - Guatemala 7
UZ - Uzbekistan 7
PK - Pakistan 6
CR - Costa Rica 5
EG - Egitto 5
LB - Libano 5
RO - Romania 5
SV - El Salvador 5
VE - Venezuela 5
DZ - Algeria 4
GR - Grecia 4
LT - Lituania 4
NP - Nepal 4
PT - Portogallo 4
KZ - Kazakistan 3
PE - Perù 3
PY - Paraguay 3
RS - Serbia 3
TN - Tunisia 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
AZ - Azerbaigian 2
BS - Bahamas 2
CY - Cipro 2
GE - Georgia 2
GH - Ghana 2
HN - Honduras 2
HU - Ungheria 2
IL - Israele 2
KH - Cambogia 2
NI - Nicaragua 2
NO - Norvegia 2
OM - Oman 2
TT - Trinidad e Tobago 2
UY - Uruguay 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AO - Angola 1
BB - Barbados 1
BO - Bolivia 1
BY - Bielorussia 1
CW - ???statistics.table.value.countryCode.CW??? 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
GD - Grenada 1
HR - Croazia 1
KE - Kenya 1
KG - Kirghizistan 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
Totale 13.668
Salva come PNG Salva come JPEG
Città #
Singapore 854
Ashburn 608
Ho Chi Minh City 404
Chandler 402
Southend 396
Fairfield 332
Hefei 331
Hanoi 326
Hong Kong 278
San Jose 258
Bologna 245
Woodbridge 165
Beijing 155
Seoul 150
Dallas 149
Ann Arbor 146
Seattle 146
Houston 139
Wilmington 139
Dong Ket 136
Abidjan 130
Santa Clara 115
Cambridge 114
New York 112
Dublin 107
Princeton 107
Council Bluffs 102
Boardman 89
Los Angeles 88
Lauterbourg 76
Helsinki 68
Milan 62
Haiphong 59
Lomé 59
Tokyo 54
Nanjing 46
Bremen 44
Munich 41
Hyderabad 40
Da Nang 39
Frankfurt am Main 39
Westminster 38
São Paulo 36
Padova 33
Sofia 31
Turin 31
Jinan 30
Bengaluru 29
Buffalo 29
Jacksonville 28
Berlin 26
Amsterdam 25
Brussels 25
Guangzhou 25
Redondo Beach 25
San Diego 25
Chicago 24
Vienna 24
Changsha 23
Redmond 23
Rome 23
Shenyang 23
Amman 22
Redwood City 22
Saint Petersburg 21
Can Tho 20
Nuremberg 20
Johannesburg 19
Bern 18
Biên Hòa 18
Fabriano 18
Florence 18
Lappeenranta 18
Ha Long 17
Quận Bình Thạnh 17
Zhengzhou 17
Nanchang 16
Shanghai 16
Tianjin 16
Atlanta 15
London 15
Thái Nguyên 15
Hải Dương 14
Naples 14
Toronto 14
Warsaw 14
Washington 14
Abeokuta 13
Falkenstein 13
Medford 13
Ninh Bình 13
Phoenix 13
Wuhan 13
Hebei 12
Bắc Ninh 11
Charlotte 11
Dhaka 11
Jakarta 11
Montreal 11
Orem 11
Totale 8.510
Salva come PNG Salva come JPEG
Nome #
Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma 719
18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease 359
Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment 272
Peripheral neuropathy induced by subcutaneous bortezomib-based induction therapy for newly diagnosed multiple myeloma. 251
Positron emission tomography with computed tomography-based diagnosis of massive extramedullary progression in a patient with high-risk multiple myeloma. 250
Treatment optimization for Multiple Myeloma: schedule-dependent synergistic cytotoxicity of pomalidomide and carfilzomib in an in vitro and ex-vivo model 238
Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes 237
The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD) 237
A 41-gene signature predicts complete response (CR) to Bortezomib-Thalidomide-Dexamethasone (VTD) as induction therapy prior to autologous stem-cell transplantation (ASCT) in multiple myeloma (MM). 226
Safety and efficacy of daratumumab in dialysis-dependent renal failure secondary to multiple myeloma 222
Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma 221
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. 221
Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study. 218
Clinical Presentation and Long‐Term Survival Outcomes of Patients With Monoclonal Gammopathy of Renal Significance (MGRS): A Multicenter Retrospective Study 213
Identification of a Maturation Plasma Cell Index through a Highly Sensitive Droplet Digital PCR Assay Gene Expression Signature Validation in Newly Diagnosed Multiple Myeloma Patients 213
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study 213
A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma 213
Circulating Multiple Myeloma Cells (CMMCs) as Prognostic and Predictive Markers in Multiple Myeloma and Smouldering MM Patients 208
HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment 206
Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens 205
Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma 205
Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study 205
Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma 204
Opposite activation of the Hedgehog pathway in CD138+ plasma cells and CD138-CD19+ B cells identifies two subgroups of patients with multiple myeloma and different prognosis 201
Diagnostic Innovations: Advances in imaging techniques for diagnosis and follow-up of multiple myeloma 196
The ALLgorithMM: How to define the hemodilution of bone marrow samples in lymphoproliferative diseases 194
Role of serum-free light chain assay for defining response and progression in immunoglobulin secretory multiple myeloma 192
Maintenance therapy with bortezomib and dexamethasone after autotransplantation for high-risk multiple myeloma 188
Thalidomide maintenance in multiple myeloma: certainties and controversies. 185
High level of circulating cell-free tumor DNA at diagnosis correlates with disease spreading and defines multiple myeloma patients with poor prognosis 184
Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency. 183
PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma 182
The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma 182
Long-term results of thalidomide and dexamethasone (thal-dex) as therapy of first relapse in multiple myeloma. 181
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy following autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma. 181
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients 181
Unique molecular assay (UMA): a next-generation sequencing targeted panel for efficient and comprehensive genomic profiling and risk stratification of multiple myeloma 178
Role of serum free light chain assay in the detection of early relapse and prediction of prognosis after relapse in multiple myeloma patients treated upfront with novel agents 177
HIF 1 Alpha: A Suitable Target for Multiple Myeloma 177
Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy 177
Long term follow-up of humoral and cellular response to mRNA-based vaccines for SARS-CoV-2 in patients with active multiple myeloma 176
A 41-Gene Signature Predicts Complete Response (CR) to Bortezomib-Thalidomide-Dexamethasone (VTD) As Induction Therapy Prior to Autologous Stem-Cell Transplantation (ASCT) in Multiple Myeloma (MM) 176
Single-Cell DNA Sequencing Reveals an Evolutionary Pattern of CHIP in Transplant Eligible Multiple Myeloma Patients 172
High Number of Copy Number Alterations and Over-Expression of Genes Involved in the Response Mechanisms to Genotoxic Stress Both Characterize Newly Diagnosed Multiple Myeloma (MM) Patients Carrying Amplified MDM4 and/or Deleted p53 169
Genomic characterization of the putative myeloma stem cells clone reveals alterations possibly correlated with the origin of disease. 165
Early Light Chains Removal and Albumin Levels with a Double Filter-Based Extracorporeal Treatment for Acute Myeloma Kidney 164
Gene expression analysis of newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted p5 164
OAB-006: A novel algorithm to identify, characterize and define the prognostic impact of complex catastrophic events in Multiple Myeloma 160
Long-term follow-up after autologous stem cell transplantation for light- and heavy-chain deposition disease. 158
High CNA level and over-expression of genes involved in response mechanisms to genotoxic stress characterize newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted TP53 156
Multi-dimensional scaling techniques unveiled gain1q&loss13q co-occurrence in Multiple Myeloma patients with specific genomic, transcriptional and adverse clinical features 155
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials 154
SIRT Regulates the Molecular Interaction Between c-MYC and HIF-1α in Multiple Myeloma 147
High levels of CRBN isoform lacking IMiDs binding domain predicts for a worse response to IMiDs-based upfront therapy in newly diagnosed myeloma patients 146
VarianThinker: a classification method to confidently approach the mutation heterogeneity in Multiple Myeloma 146
Rare, but complex chromosomal rearrangements, defined "Chromoanagenesis”, caused by single-step or stepwise catastrophic genomic events, significantly impact on Multiple Myeloma patients 142
Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis. 141
SIRT regulates the molecular interaction between c-MYC and HIF-1 alpha in multiple myeloma 136
Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation 135
Impact Of p53 Impaired Function On Outcomes Of Multiple Myeloma Patients Carrying Deleted TP53 and/Or Amplified MDM4 134
Emerging and current treatment combinations for transplant-ineligible multiple myeloma patients 131
Impact of Anti-CD38 Monoclonal Antibody Therapy on CD34+ Hematopoietic Stem Cell Mobilization, Collection, and Engraftment in Multiple Myeloma Patients—A Systematic Review 127
Interference of daratumumab and efficacy of plerixafor on haematopoietic stem cell collection in Multiple Myeloma 126
Antibody-drug conjugates, bispecific antibodies and CAR-T cells therapy in multiple myeloma 125
Case Report: Uncommon co-occurrence of different renal histopathological entities in a patient with multiple myeloma and lymphoplasmacytic lymphoma 124
The Value of 18F-FDG PET/CT after Autologous Stem Cell Transplantation (ASCT) in Patients Affected by Multiple Myeloma (MM): Experience With 77 Patients 123
Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients 120
Subcutaneous bortezomib-containing regimens as up-front treatment of newly diagnosed transplant-eligible multiple myeloma patients: a retrospective, non-interventional observational study 101
Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma 99
Bispecific Antibodies and CAR T in Multiple Myeloma: Appropriate Selection of Patients and Sequencing 98
OAB-057: Temporal-weight estimation of the copy number alterations of of 1384 Multiple Myeloma patients defines an ancestrality index impacting patients survival 97
Exceptional long-term responses from OCEAN and HORIZON trials: melflufen-dexamethasone as an expansion of treatment options for relapsed/refractory multiple myeloma in the era of new immunotherapies? 94
Proteasome inhibitors: Bortezomib in multiple myeloma 94
Abstract 2700: Negative selective pressure exerted by maintenance therapy promotes the extinction of sub-clones carrying high-risk lesions in multiple myeloma 92
IMPLEMENTATION OF NEXT GENERATION SEQUENCING AS BEST TOOL FOR ROUTINE EVALUATION OF MINIMAL RESIDUAL DISEASE IN THE DAILY PRACTICE OF MULTIPLE MYELOMA PATIENTS 88
Ten-year experience on home care for patients with plasma cell disorders: bringing optimal therapy home 87
A multicenter observational retrospective study of second-line treatment with daratumumab–bortezomib–dexamethasone (DaraVd) in multiple myeloma patients refractory to lenalidomide 81
The road to cure in multiple myeloma: Incorporation of novel agents into autologous stem cell transplantation 65
Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial 60
Totale 13.923
Salva come PNG Salva come JPEG
Categoria #
all - tutte 38.271
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 38.271
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.019 0 52 60 84 88 49 25 79 48 128 203 203
2022/20231.549 136 217 56 256 106 129 45 96 263 52 118 75
2023/2024590 40 83 33 50 46 149 25 79 13 19 31 22
2024/20251.973 113 193 172 173 207 78 144 68 51 228 177 369
2025/20265.870 538 1.031 461 455 516 281 504 175 1.063 406 237 203
2026/2027348 162 186 0 0 0 0 0 0 0 0 0 0
Totale 13.923